Acadian Asset Management’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,230,770
| Closed | -$1.01M | – | 1754 |
|
|
2025
Q1 | $1.01M | Sell |
1,230,770
-73,741
| -6% | -$71K | ﹤0.01% | 934 |
|
|
2024
Q4 | $1.24M | Hold |
1,304,511
| – | – | ﹤0.01% | 882 |
|
|
2024
Q3 | $1.3M | Buy |
1,304,511
+74,601
| +6% | +$82.6K | ﹤0.01% | 863 |
|
|
2024
Q2 | $1.52M | Buy |
1,229,910
+455,351
| +59% | +$464K | ﹤0.01% | 857 |
|
|
2024
Q1 | $1M | Buy |
774,559
+113,618
| +17% | +$130K | ﹤0.01% | 837 |
|
|
2023
Q4 | $825K | Buy |
660,941
+45,996
| +7% | +$50.9K | ﹤0.01% | 911 |
|
|
2023
Q3 | $798K | Buy |
614,945
+36,909
| +6% | +$59.6K | ﹤0.01% | 903 |
|
|
2023
Q2 | $993K | Buy |
578,036
+101,739
| +21% | +$162K | ﹤0.01% | 876 |
|
|
2023
Q1 | $694K | Buy |
476,297
+70,473
| +17% | +$135K | ﹤0.01% | 973 |
|
|
2022
Q4 | $657K | Buy |
405,824
+197,239
| +95% | +$454K | ﹤0.01% | 964 |
|
|
2022
Q3 | $697K | Buy |
208,585
+61,274
| +42% | +$277K | ﹤0.01% | 899 |
|
|
2022
Q2 | $536K | Buy |
147,311
+143,744
| +4,030% | +$652K | ﹤0.01% | 954 |
|
|
2022
Q1 | $25K | Buy |
+3,567
| New | +$30.4K | ﹤0.01% | 1549 |
|
Acadian Asset Management's KRON Position: Q2 2025 in Review
Acadian Asset Management sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 1,230,770 shares — an estimated $1.01M sold.
Acadian Asset Management first reported a position in KRON in Q1 2022 and held it in 13 quarters. The position peaked at $1.52M in Q2 2024. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Acadian Asset Management reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Acadian Asset Management sold 1,230,770 Kronos Bio shares in Q2 2025, an estimated $1.01M.
- Acadian Asset Management first reported a position in Kronos Bio in Q1 2022 and held it in 13 quarters.
- Acadian Asset Management's Kronos Bio position peaked at $1.52M in Q2 2024.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Acadian Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.